ASH Annual Meeting | Conferences

Responses to Cilta-Cel Durable for Nearly 2 Years Across Several R/R Multiple Myeloma Subgroups

December 15, 2021

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.